Author

T. Vidotto

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 4 Research Focus:differential expression· 3 Organism:human· 3 Approach:statistical model· 3 Research Focus:cell type annotation· 2 Research Focus:cancer & tumor microenvironment· 1 Approach:experimental assay· 1 Organism:mouse· 1

Frequent Co-Authors

M. Koti· 2 shared A. AfriyieAsante· 1 shared C. Hardy· 1 shared C. Jackson· 1 shared C. M Melo· 1 shared D. F. Sanchez· 1 shared D. M. Berman· 1 shared D. R. Siemens· 1 shared

Activity by Year

2019-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 14 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

M. Koti

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Pan-genomic analysis shows hemizygous PTEN loss tumors are associated with immune evasion and poor outcome

T. Vidotto, C. M Melo, W. Lautert-Dutra, L. P. Chaves, R. Borges dos Reis, J. Squire

The paper analyzes PTEN copy number in tumors, finding hemizygous loss correlates with immune evasion and poor survival similar to homozygous loss.

bioRxiv · Sep 16, 2022 · PreprintCancer Biology

Sexual dimorphism in outcomes of non-muscle invasive bladder cancer: a role of CD163+ M2 macrophages, B cells and PD-L1 immune checkpoint.

S. Chenard, C. Jackson, T. Vidotto, L. Chen, C. Hardy, T. Jamaspishvilli, D. M. Berman, D. R. Siemens, M. Koti

This study identifies sexual dimorphism in NMIBC immune microenvironment, showing higher CD163+ macrophages and PD-L1 in female tumors, linked to worse recurrence-free survival.

bioRxiv · Jan 23, 2021Immunology

Transcriptional landscape of PTEN loss in primary prostate cancer

E. L. Imada, D. F. Sanchez, W. Dinalankara, T. Vidotto, E. M. Ebot, S. Tyekucheva, G. R. Franco, L. Mucci, M. Loda, E. M. Schaeffer, T. Lotan, L. Marchionni

The paper identifies a transcriptomic signature of PTEN loss in prostate cancer, revealing immune system activation and cell-cycle gene upregulation, and expands it to include non-coding RNAs.

bioRxiv · Oct 8, 2020 · PreprintCancer Biology

Chemotherapy induced immunogenic cell death alters response to exogenous activation of STING pathway and PD-L1 immune checkpoint blockade in a syngeneic murine model of ovarian cancer.

S. Nersesian, N. Shakfa, N. Peterson, T. Vidotto, A. AfriyieAsante, E. Lightbody, M. Koti

This study shows that chemotherapy type affects the response to STING pathway activation and PD-L1 blockade in a murine model of ovarian cancer, with carboplatin + STING + PD-L1 providing the best survival.

bioRxiv · Oct 30, 2019 · PreprintCancer Biology